Aspects of Peptidomimetics - Peptide and Protein Design for Biopharmaceutical Applications - page 129

[362] P. Grieco, A. Carotenuto, P. Campiglia, L. Marinelli, T. Lama, R. Patacchini,
P. Santicioli, C. A. Maggi, P. Rovero and E. Novellino, Urotensin-II receptor
ligands. From agonist to antagonist activity, J.Med.Chem ., 48, 7290-7297
(2005).
[363] S. Foister, L. L. Taylor, J. J. Feng, W. L. Chen, A. Lin, F. C. Cheng, A. B. Smith and
R. Hirschmann, Design and synthesis of potent cystine-free cyclic hexapeptide
agonists at the human urotensin receptor, Org.Lett ., 8, 1799-1802 (2006).
[364] A. Carotenuto, P. Griecio, P. Rovero and E. Novellino, Urotensin-II receptor
antagonists, Curr.Med.Chem ., 13, 267-275 (2006).
[365] S. Flohr, M. Kurz, E. Kostenis, A. Brkovich, A. Fournier and T. Klabunde,
Identification of nonpeptidic urotensin II receptor antagonists by virtual screening
based on a pharmacophore model derived from structure-activity relationships and
nuclear magnetic resonance studies on urotensin II, J.Med.Chem ., 45, 1799-1805
(2002).
[366] F. Lehmann, A. Pettersen, E. A. Currier, V. Sherbukhin, R. Olsson, U. Hacksell and
K. Luthman, Novel potent and efficacious nonpeptidic urotensin II receptor agonists,
J.Med.Chem ., 49, 2232-2240 (2006).
[367] D. K. Luci, S. Ghosh, C. E. Smith, J. Qi, Y. Wang, B. Haertlein, T. J. Parry, J. Li,
H. R. Almond, L. K. Minor, B. P. Damiano, W. A. Kinney, B. E. Maryano and
E. C. Lawson, Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists:
Synthesis, SAR, and in vivo assessment, Bioorg.Med.Chem.Lett ., 17, 6489-6492
(2007).
[368] P. M. Fischer, Peptide, peptidomimetic, and small-molecule antagonists of the
p53-HDM2 protein-protein interaction, Int. J. Pept. Res. Ther. , 12, 3-19 (2006).
[369] J. K. Murray and S. H. Gellman, Targeting protein-protein interactions: Lessons
from p53/MDM2, Biopolymers , 88, 657-686 (2007).
[370] A. S. Dudkina and C. W. Lindsley, Small molecule protein-protein inhibitors for the
p53-MDM2 interaction, Curr. Top. Med. Chem ., 7, 952-960 (2007).
[371] C. Garcia-Echeverria, P. Chene, M. J. J. Blommers and P. Furet, Discovery of potent
antagonists of the interaction between human double minute 2 and tumor suppres-
sor p53, J. Med. Chem ., 43, 3205-3208 (2000).
[372] K. Sakurai, C. Schubert and D. Kahne, Crystallographic analysis of an 8-mer p53
peptide analogue complexed with MDM2, J. Am. Chem. Soc ., 128, 11000-11001
(2006).
[373] J. A. Kritzer, O. M. Stephens, D. A. Guarracino, S. K. Reznik and A. Schepartz,
beta-Peptides as inhibitors of protein-protein interactions, Bioorgan. Med. Chem .,
13, 11-16 (2005).
[374] J. A. Kritzer, M. E. Hodsdon and A. Schepartz, Solution structure of a beta-peptide
ligand for hDM2, J. Am. Chem. Soc ., 127, 4118-4119 (2005).
[375] F. Bernal, A. F. Tyler, S. J. Korsmeyer, L. D. Walensky and G. L. Verdine,
Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide,
J. Am. Chem. Soc ., 129, 2456 (2007).
[376] K. Sakurai, H. S. Chung and D. Kahne, Use of a retroinverso p53 peptide as an
inhibitor of MDM2, J. Am. Chem. Soc ., 126, 16288-16289 (2004).
[377] T. Hara, S. R. Durell, M. C. Myers and D. H. Appella, Probing the structural
requirements of peptoids that inhibit HDM2-p53 interactions, J. Am. Chem.
Soc ., 128, 1995-2004 (2006).